Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Alexander van Akkooi MD, PhD, FRACS
Alexander C. J. van Akkooi MD, PhD, FRACS Associate Editor
Barbara Burtness MD
Barbara Burtness MD Advisory Board
Eric Jonasch MD
Eric Jonasch MD Advisory Board
See All Experts
featured
Published in Oncology

Expert Opinion / Interview · October 15, 2019

Margetuximab Plus Pembrolizumab for Patients With HER2+ GE Junction Adenocarcinoma

Elizabeth Smyth MD
Daniel Catenacci MD
Interview with
Daniel Catenacci MD

 

 Save  Recommend
 Share

Further Reading

Most Watched This Week

Related Videos